Synopsis

Keywords: Body: Body

Focal therapy (FT), where a specific clinically significant PCa (csPCa) is ablated, is a treatment option for localized intermediate-risk disease. The aim of FT is to eradicate csPCa while minimizing morbidity associated with whole-gland treatment. MRI allows spatial resolution in all 3 planes for precise treatment definition. Additionally, MR thermography provides thermal feedback during treatment. Non-perfused volume can be assessed following treatment providing assessment of the ablated area. The ExAblate 2100 Prostate (Insightec Inc., Haifa) is a transrectal, MRI guided focused ultrasound (MRgFUS) system. This presentation will outline the technique and existing literature of MRgFUS treatment for intermediate risk PCa.